ストックスクリーナーアプリを入手
16.49
5.88%
-1.03
アフターアワーズ：
16.50
0.01
+0.06%
前日終値:
$17.52
開ける：
$17.52
24時間の取引高:
701.84K
Relative Volume:
0.69
時価総額：
$1.01B
収益：
-
当期純損益:
$-221.04M
株価収益率:
-4.4396
EPS:
-3.7143
ネットキャッシュフロー:
$-178.65M
1週間 パフォーマンス:
-3.57%
1か月 パフォーマンス:
-9.45%
6か月 パフォーマンス:
+37.88%
1年 パフォーマンス:
+112.23%
1日の値動き範囲:
$16.14
$17.52
1週間の範囲:
$16.14
$17.99
52週間の値動き範囲:
$5.68
$19.43
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Compare CGEM vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
16.49 | 1.07B | 0 | -221.04M | -178.65M | -3.7143 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-17 | 開始されました | Citigroup | Buy |
| 2026-02-02 | 開始されました | Guggenheim | Buy |
| 2025-08-21 | 再開されました | H.C. Wainwright | Buy |
| 2025-06-11 | 再開されました | Stifel | Buy |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-05-01 | 開始されました | Stifel | Buy |
| 2024-04-15 | 開始されました | William Blair | Outperform |
| 2024-02-15 | 開始されました | Wedbush | Outperform |
| 2023-06-15 | 開始されました | TD Cowen | Outperform |
| 2022-11-21 | 開始されました | BTIG Research | Buy |
| 2021-04-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | 開始されました | Evercore ISI | Outperform |
| 2021-02-02 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-02-02 | 開始されました | SVB Leerink | Outperform |
| 2021-02-01 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Cullinan Therapeutics Inc (CGEM) 最新ニュース
Cullinan Therapeutics stock rises on FDA meeting for CLN-049 By Investing.com - Investing.com Canada
Cullinan Therapeutics stock rises on FDA meeting for CLN-049 - Investing.com
Why is Cullinan Therapeutics stock climbing today? By Investing.com - Investing.com Canada
Cullinan Therapeutics (CGEM) Advances AML Treatment with FDA Fee - GuruFocus
Cullinan Therapeutics advances CLN-049 to Phase 2 after positive FDA feedback - Traders Union
Cullinan Therapeutics Announces Positive FDA Feedback for CLN-049 and Plans Potentially Registrational Phase 2 Study in Relapsed/Refractory AML - Quiver Quantitative
Cullinan Therapeutics Announces Positive End-of-Phase 1 - GlobeNewswire
Cullinan Therapeutics Inc (CGEM) Institutional Confidence - TradingKey
Cullinan Therapeutics Inc (CGEM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cullinan Therapeutics Inc (CGEM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cullinan Therapeutics Inc (CGEM) Valuation: PE, PB & Fair Value Analysis - TradingKey
CGEM|Cullinan Therapeutics Inc|Price:17.775|Chg%:+0.675 - TradingKey
Cullinan Therapeutics Inc (CGEM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cullinan Therapeutics Inc (CGEM) Cash Flow - TradingKey
ETFs Investing in Cullinan Therapeutics, Inc. Stocks - TradingView
CGEM|Cullinan Therapeutics Inc|Price:17.700|Chg%:+0.600 - TradingKey
Cullinan Therapeutics Inc (CGEM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cullinan Therapeutics Inc (CGEM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cullinan Therapeutics, Inc. Revenue Breakdown – NASDAQ:CGEM - TradingView
CGEM|Cullinan Therapeutics Inc|Price:17.100|Chg%:-0.180 - TradingKey
Cullinan Therapeutics (CGEM) Edges Higher as Modest Gains Signal Steady SentimentMACD Signal Stocks - dars.gov.et
Cullinan CSO sells shares, exercises options | CGEM Insider Trading - Stock Titan
Enterprise value to EBIT forward of Cullinan Therapeutics, Inc. – NASDAQ:CGEM - TradingView
Price to sales forward of Cullinan Therapeutics, Inc. – NASDAQ:CGEM - TradingView
CGEM (NASDAQ) insider resale notice: 8,000 shares proposed, prior 10b5-1 sales noted - Stock Titan
Enterprise value to revenue forward of Cullinan Therapeutics, Inc. – NASDAQ:CGEM - TradingView
Price to earnings forward of Cullinan Therapeutics, Inc. – NASDAQ:CGEM - TradingView
CGEMCullinan Therapeutics Inc Latest SEC Filings - Finviz
Cullinan Therapeutics (CGEM) CFO adds 1,541 shares through ESPP purchase - Stock Titan
Cullinan Therapeutics (CGEM) CLO adds 2,470 ESPP shares at $8.60 - Stock Titan
EGFR-NSCLC Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Dizal Pharma, Eli Lilly, Cullinan Oncology, Taiho Pharma, AstraZeneca, J&J Innovative Medicine - Barchart.com
Cullinan Therapeutics, Inc. Actuals & Estimates (NASDAQ:CGEM) - TradingView
CGEM Forecast — Price Target — Prediction for 2027 - TradingView
Cullinan Therapeutics (CGEM) Is Up 31.0% After Autoimmune T Cell Engager Data – Has The Bull Case Changed? - Sahm
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Cullinan Oncology stock hits 52-week high at $17.97 By Investing.com - Investing.com Australia
Cullinan Oncology stock hits 52-week high at $17.97 - Investing.com UK
Cullinan Therapeutics (CGEM) Is Up 27.1% After Autoimmune T Cell Engager Data Sparks Immune-Reset Hopes - Yahoo Finance
Cullinan Therapeutics Inc (CGEM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cullinan Therapeutics (CGEM) Citi’s 2026 Virtual Oncology Leadership Summit Summary - Quartr
Cullinan Therapeutics (CGEM) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Cullinan Therapeutics (CGEM) Surges 4%: Key Levels to Watch After Recent UptickOpening Range Breakout - dars.gov.et
CULLINAN THERAPEUTICS INC (CGEM) Stock Chart - ChartMill
Cullinan Therapeutics (CGEM) director receives 21,781-share stock option grant - Stock Titan
Cullinan Therapeutics (CGEM) grants director 25,319 stock options - Stock Titan
Director David D. Meek granted 25,319 options at Cullinan Therapeutics (CGEM) - Stock Titan
Cullinan Therapeutics (CGEM) director receives stock options for 25,319 shares - Stock Titan
Cullinan Therapeutics (CGEM) grants director Mittie Doyle 21,781 stock options - Stock Titan
Cullinan Therapeutics (CGEM) director awarded 25,319 options at $13.55 strike - Stock Titan
Cullinan Therapeutics Inc (CGEM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cullinan Therapeutics shareholders elect directors and approve proposals at annual meeting - Investing.com
Cullinan Therapeutics Inc (CGEM) 財務データ
収益
当期純利益
現金流量
EPS
Cullinan Therapeutics Inc (CGEM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Michaelson Jennifer | Chief Scientific Officer |
Jul 06 '26 |
Sale |
17.82 |
8,000 |
142,560 |
162,844 |
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):